Rating Scales for Parkinson’s Disease African and Telemedicine Initiatives Movement Disorder Society Cameroon Christopher G. Goetz, Chicago, USA.

Slides:



Advertisements
Similar presentations
Rubrics for Transition IV: for Students with Severe Disabilities by Dr
Advertisements

MOTOR NEURON DISEASE The motor neuron diseases (or motor neuron diseases) (MND) are a group of neurological disorders that selectively affect motor neurons.
Child Protection Rapid Assessment Tool
CAPA California Alternate Performance Assessment (CAPA) Presented by Contra Costa SELPA with information provided by California Department of Education.
WP4 – Task 4.4 LCA Activities
Evaluation of Movement Disorders
KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN BADAN PENGEMBANGAN SUMBER DAYA MANUSIA PENDIDIKAN DAN KEBUDAYAAN DAN PENJAMINAN MUTU PENDIDIKAN AUTHENTIC ASSESSMENT.
Foreign Language and Area Studies ( FLAS ) Fellowships.
The PARticulars of Parkinson’s Disease
A joint Australian, State and Territory Government Initiative Rater and Clinical Utility Training Older Persons “Sharing Information to Improve Outcomes”
Parkinson’s Disease Dr.Shamekh M. El-Shamy. Definition:
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Screening By building screening for symptoms of VCI into regular workflows or practice, health care providers are participating in Taking Action to address.
Parkinson’s Test Device Development Erin Sikkel and Tiffany Feltman.
A Clinician's Approach to Fatigue of Cancer Patients
Taking a Look at the DSM V KIMMIE JORDAN, MS, CPRP, LADAC PSRANM 21 ST ANNUAL CONFERENCE “THE ART OF RECOVERY ”
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
CAHPS Overview Clinician & Group Surveys: Practical Options for Implementation and Use AHRQ ANNUAL MEETING SEPTEMBER 18, 2011 Christine Crofton, PhD CAHPS.
NEUROLOGICAL DISORDERS. Dementia  A degenerative syndrome characterized by deficits in memory, language, and mood.  The most common form: Alzheimer’s.
The Revised CDER Regional Center Train-The-Trainers 2007.
Game.reha.lviv.ua International Clinic of Rehabilitation WEB-BASED HOME REHABILITATION GAMING SYSTEM.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
Cognitive Interviewing for Question Evaluation Kristen Miller, Ph.D. National Center for Health Statistics
Using stroke scales to assess the patient – Rankin and NIHSS
FDA Approach to Review of Outcome Measures for Drug Approval and Labeling: Content Validity Initiative on Methods, Measurement, and Pain Assessment in.
Presented by David J. Kupfer, MD Chair of the DSM-5 Task Force CARNEGIE LIBRARY OF PITTSBURGH SATURDAY, OCTOBER 26, 2013 The Making of the DSM-5.
Duodenal Levodopa Treatment in advanced Parkinson’s Disease
Understanding MYP Criteria
Non-motor symptoms of Parkinson’s disease This educational material has been supported by Abbott.
Effect of an Eight-Week Adaptive Yoga Program on Mobility, Function, and Outlook in Individuals with Parkinson’s Disease.
Renaissance Academy World Language Program Assessment.
Miller Function & Participation Scales (M-FUN)
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Innovations in Parkinson’s Diagnosis & Treatment: A Personal Story Dr. Kenneth E. Keirstead Excellence in Aging Care Symposium September 25-27, 2013.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Score the Washington Educational Technology Assessments Educational Technology.
Arbitre Consulting, Inc.
1 National Outcomes and Casemix Collection Training Workshop Adult Ambulatory.
PARKINSON’S DISEASE By: AARUSHI JAIN AMRUTA KAMBLE ANNETT MARY JACOB AVANTI DEO M.Sc. PRIST (09-11)
Improvement of life quality and non motor symptoms relief in patients with advanced Parkinson's disease. Natalia Prican Andra Oltean Doctor Jozsef Attila.
PARKINSON’S DISEASE BY: NICOLE MABARDI & SHAINA JOSEPH.
CAHPS PATIENT EXPERIENCE SURVEYS AHRQ ANNUAL MEETING SEPTEMBER 2012 Christine Crofton, PhD CAHPS Project Officer.
Translation and Linguistic Validation of the Self-completed Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS) scale for use in a Libyan population.
Teaching NeuroImages A 54-year-old man with progressive muscle weakness, hand tremor, tongue and perioral fasciculation Neurology Resident and Fellow Section.
PARKINSON’S DISEASE.
The Substantia Nigra THE BRAIN Symptoms differ from every person suffering from the disease. There are two types of symptoms, primary, secondary.
Canadian Best Practice Recommendations for Stroke Care Recommendation 1: Public Awareness and Patient Education (Updated 2008)
Parkinson’s Disease in Africa Jacques Doumbé MD Department of Neurology Douala Laquintinie Hospital Cameroon.
UBC Dietetics Major Modules and Forms Update
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
Parkinson’s Disease: Updating the UPDRS February 20, 2014 Glenn T. Stebbins, PhD Department of Neurological Sciences Rush University Medical Center Chicago,
Quantification of dyspnea using descriptors: Development and initial testing of the Dyspnea-12 J Yorke, S H Moosavi, C Shuldham, P W Jones (Thorax
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Sleep and Parkinson’s Disease
Understanding Parkinsons Disease
Parkinson’s Disease Jose S. Santiago M.D..
Non motor features in Essential Tremor: A Comparison  with Parkinson’s Disease Y. Şengül1, H.S. Şengül2, S. Yücel3, S. Kural Yücekaya4 1Department of.
Predicting Fall Risk in Patients with Parkinson’s Disease
Designing Classroom Language Tests
mRS & NIHSS Training and Certification Procedure
Parkinson's disease Parkinson's disease (PD) is the second-most common
Bruce Waslick, MD Medical Director UMass / Baystate MCPAP Team
Rhematoid Rthritis Respiratory disorders
TELPAS Alternate Student Eligibility
ADVANCED PARKINSON'S DISEASE:
Caregiver Support Program
Development of Patient Defined Migraine Assessment
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Presentation transcript:

Rating Scales for Parkinson’s Disease African and Telemedicine Initiatives Movement Disorder Society Cameroon Christopher G. Goetz, Chicago, USA

Learning Objectives At the end of this presentation, I will: Understand the scientific justification for using rating scales in your Cameroon neurological practice for Parkinson’s disease Use the Hoehn and Yahr Stages for categorizing patients and the MDS-UPDRS for measuring severity in Parkinson’s disease Access available educational resources through the Movement Disorder Society

Outline Overview of scale usage in Movement Disorders Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

Outline Overview of scale usage in Parkinson’s disease Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

What do scales do for a clinician? Scales provide a numeric code for a sign or symptom Can indicate Presence (1) or Absence (0) Can indicate Severity 0-absent 1-minimal 2-mild 3-moderate 4-severe

Usual primary measures Motor Tremor Bradykinesia Rigidity Gait and balance Non-motor Depression Cognition

Scale requirements Three key attributes are needed for a good scale. Validity Reliability Responsivity Ideally, tested and validated in the given culture Training is necessary so that scales are used uniformally

Outline Overview of scale usage in Movement Disorders Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

Hoehn and Yahr Stages Developed in the 1960’s Describes categories overall impairment Patients do not necessarily progress sequentially across all stages Internationally respected as a means of immediate global communication on patients with PD

Hoehn and Yahr Stages 0—no parkinsonism 1—Unilateral involvement only 2—Bilateral involvement; normal balance 3—Mildly impaired postural reflexes, but disability is mild or moderate 4—Postural reflexes significantly impaired— disability marked, walking not safe 5—Confined to chair or bed—no safe standing

Patient examples Extracted from Common Movement Disorders: Video educational program Harold L. Klawans, Christopher G. Goetz and Caroline M. Tanner Raven Press 1990.

Hoehn and Yahr Stages

Important points In speaking with colleagues internationally, the Hoehn and Yahr stage immediately communicates an overall picture of parkinsonism Whereas Stages 2-5 represent progressive disability, Stage 1 is not necessarily less impaired than Stage 2. With levodopa available, most patients at any one time are Stage 2 and Stage 3 If a patient has had symptoms of parkinsonism for less than 2 years and is Stage 3, rethink the diagnosis.

Outline Overview of scale usage in Movement Disorders Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

MDS-UPDRS Designed to be a comprehensive rating of PD To cover Motor and non-Motor elements Fully validated in English version Several languages also available

MDS-UPDRS I: Non-motor Experiences of Daily Living 13 items: Interview (6) Questionnaire (7) II: Motor Experiences of Daily Living 13 items all patient questionnaire III: Motor Section - 18 items by examiner IV: Motor Complications 6 items: Interview: dyskinesias (3); fluctuations (3) Total: 50 Items (65 scores)

MDS-UPDRS Detailed instructions All scores are anchored to clinical statement: 0 = normal 1 = slight 2 = mild 3 = moderate 4 = severe Official Appendix for additional focus

MDS-UPDRS I. I. NON-MOTOR ASPECTS OF EXPERIENCES OF DAILY LIVING (nM-EDL) INTERVIEW QUESTIONNAIRE 1. COGNITVE IMPAIRMENT 1. SLEEP 2. HALLUCINATIONS 2. STAYING AWAKE 3. DEPRESSED MOOD 3. PAIN/SENSORY 4. ANXIOUS MOOD 4. URINARY FUNCTION 5. APATHY 5. CONSTIPATION 6. DOPAMINE 6. LIGHTHEADEDNESS DYSREGULATION ON STANDING 7. FATIGUE

MDS UPDRS II. MOTOR ASPECTS OF EXPERIENCES OF DAILY LIVING (M-EDL) — all part of questionnaire 1. Speech 8. Other fine motor tasks 2. Handling saliva 9. Tremor impact on activities 3. Swallowing & chewing 10. Turning in bed and 4. Feeding adjusting bed clothes 5. Dressing 11. Getting in and out of bed, 6. Hygiene car or deep chair 5. Dressing 12. Balance and walking 7. Handwriting 13. Gait Freezing

MDS UPDRS III. MOTOR EXAMINATION: 1. Speech10. Gait 2. Facial Expression11. Freezing of Gait 3. Rigidity 12. Postural Stability 4. Finger Tapping13. Posture 5. Hand Movements 14. Body Bradykinesia 6. Pronation-supination15. Postural Tremor of Hands 7. Toe Tapping 16. Kinetic Tremor of Hands 8. Leg Agility 17. Rest Tremor Amplitude 9. Arising from chair 18. Rest Tremor Consistency

MDS UPDRS IV. MOTOR COMPLICATIONS: A. DYSKINESIAS [exclusive of OFF-state dystonia] 1. Time spent with dyskinesias 2. Functional impact of dyskinesias 3. Painful off-state dystonia B. MOTOR FLUCTUATIONS 3. Time spent in the off state 4. Functional impact of fluctuations 5. Complexity of motor fluctuations

Instructions Written instructions provided for uniformity and clarity of application These instructions will be reinforced in Teaching Tape Overview description on methodology Item by item instructions

Interviewing patient/caregiver Complex questions on behavior and motor complications Present the concept being assessed Ground rules: Usual, most of the time Past week Options Any problem? (0) If yes, start with option 2 Work up or down Confirm

Video demonstration

Apathy

Questionnaire 20 questions (non-motor and motor experiences of daily living) 7 th grade reading level Source: Patient, Patient + caregiver, caregiver only Rater can explain, but not answer the questions

Questionnaire

Motor Objective evaluation (Part III) Instructions provided for testing methods Rater indicates On or OFF state If on levodopa, notes time of last dose All items are anchored with 0: normal 1: Slight 2: Mild 3: Moderate 4- Severe

Patient examples Goetz CG et al. MDS-UPDRS: scale presentation and clinimetric testing program. Mov Disord 2008;23: Goetz CG et al. Teaching program for the MDS- UPDRS. Mov Disord 2010;25: Teaching module available on MDS website:

Finger Taps

Postural Stability

Time Required: 35 minutes Original UPDRS 40 minutes MDS-UPDRS Parts Ia 10 minutes to conduct Parts Ib, II To be self administered 5 minutes to review Parts III, IV 20 minutes

Appendix Guidelines for use of additional scales for non- motor assessments Based on Task Force of PD Rating Scales publications Recommended Suggested Ongoing updates:

Teaching Program Teaching DVD developed covering entire scale Part III Certificate exercise Expert panel: S Fahn, W Poewe, CM Tanner Loaded on MDS website for annual certification as a MDS-member benefit: Training and testing available as part of this Cameroon initiative.

Training Certificate Raters will rate 4 test cases Expert panel ranges as the certification standard MDS members and participants in the Cameroon program: No charge:

Non-English Official Translations Complete and approved Completed ratings being analyzed Field testing ongoing Cognitive pre- testing Preliminary set up organization Spanish Italian French Estonian German Slovak Japanese Russian HungarianChinese Korean Hebrew Thai Dutch Turkish Hindi Portuguese Serbian Greek Polish

Non-English translations Application on MDS website Language teams will initiate process with an application Translation/back translation of English version Individual items may need to be tested Full clinimetric program initiated (350 PD patients) Data submitted to central data analysis center To qualify as official, each new translation will meet factor structure similarity to original (English) version.

Outline Overview of scale usage in Movement Disorders Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

Rating Scales reviews by MDS Regularly published reviews of scales focusing on specific elements of PD Sleep Depression Cognition Dyskinesia Fluctuations Psychosis Dysautonomia Quality of Life Fatigue Consolidated in MDS-UPDRS Appendix on MDS website (

Learning Objectives At the end of this presentation, I now: Understand the scientific justification for using rating scales in your Cameroon neurological practice for Parkinson’s disease Use the Hoehn and Yahr Stages for categorizing patients and the MDS-UPDRS for measuring severity in Parkinson’s disease Access available educational resources through the Movement Disorder Society

Outline Overview of scale usage in Movement Disorders Review of two primary scales Hoehn and Yahr stages MDS-Unified Parkinson’s Disease Rating Scale Other resources Discussion

Acknowledgements and Future Contacts This program is supported by the Movement Disorders Society Dr. Goetz and his Chicago center are supported by the Parkinson’s Disease Foundation as a Parkinson Research Center For future contact:

The International PD and Movement Disorder Society The MDS gives you the opportunity for free MDS membership for 2 years The use of educational materials and travel grants for International Congresses The possibility of international rating scales training certificates.